Elevated hepatic transaminases associated with telithromycin therapy: A case report and literature review

American Journal of Health-System Pharmacy

Volumn 65, Issue 1, 2008, Pages 37-41

  Bolesta, Scott ^a,b   Roslund, Brian P ^c  

^a WILKES UNIVERSITY   (United States)

^b Mercy Hospital   (United States)

^c THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Anticoagulants; Antiinflammatory agents; Enoxaparin; Gastrointestinal drugs; Ibuprofen; Liver diseases; Macrolides; Pantoprazole; Respiratory tract infections; Telithromycin; Toxicity

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; IBUPROFEN; PANTOPRAZOLE; TELITHROMYCIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; ERYTHROCYTE SEDIMENTATION RATE; FOLLOW UP; HUMAN; LABORATORY DIAGNOSIS; LIVER CELL DAMAGE; MALE; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VIRUS HEPATITIS;

EID: 37849011355     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070164     Document Type: Article

References (35)

1. Nguyen M, Chung EP. Telithromycin: the first ketolide antimicrobial. Clin Ther. 2005; 27:1144-63.
2. Kasbekar N, Acharya PS. Telithromycin: the first ketolide for the treatment of respiratory infections. Am J Health-Syst Pharm. 2005; 62:905-16.
3. Shain CS, Amsden GW. Telithromycin: the first of the ketolides. Ann Pharmacother. 2002; 36:452-64.
4. Zhanel GG, Walters M, Noreddin A et al. The ketolides: a critical review. Drugs. 2002; 62:1771-804.
5. Ketek (telithromycin) package insert. Bridegwater, NJ: Sanofi-Aventis; 2007 Feb.
6. Carbon C, Moola S, Velancsics I et al. Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia. Clin Microbiol Infect. 2003; 9:691-703.
7. Roos K, Brunswig-Pitschner C, Kostrica R et al. Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis. Chemotherapy. 2002; 48:100-8.
8. Tellier G, Niederman MS, Nusrat R et al. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother. 2004; 54:515-23.
9. Fogarty CM, Patel TC, Dunbar LM et al. Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study. BMC Infect Dis. 2005; 5:43.
10. Hagberg L, Torres A, van Rensburg D et al. Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia. Infection. 2002; 30:378-86.
11. Clay KD, Hanson JS, Pope SD et al. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med. 2006; 144:415-20.
12. Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 2003; 349:474-85.
13. Ostapowicz G, Fontana RJ, Schiodt FV et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002; 17; 137:947-54.
14. Bjornsson E. Drug-induced liver injury: Hy's rule revisited. Clin Pharmacol Ther. 2006; 79:521-8.
15. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30:239-45.
16. Pullman J, Champlin J, Vrooman PS Jr. Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults. Int J Clin Pract. 2003; 57:377-84.
17. Van Rensburg DJ, Matthews PA, Leroy B. Efficacy and safety of telithromycin in community-acquired pneumonia. Curr Med Res Opin. 2002; 18:397-400.
18. Mathers DL, Hassman J, Tellier G. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults. Clin Ther. 2004; 26:48-62.
19. Quinn J, Ruoff GE, Ziter PS. Efficacy and tolerability of 5-day, once-daily telithromycin compared with 10-day, twice-daily clarithromycin for the treatment of group A beta-hemolytic streptococcal tonsillitis/pharyngitis: a multicenter, randomized, double-blind, parallel-group study. Clin Ther. 2003; 25:422-43.
20. Norrby SR, Rabie WJ, Bacart P et al. Efficacy of short-course therapy with the ketolide telithromycin compared with 10 days of penicillin V for the treatment of pharyngitis/tonsillitis. Scand J Infect Dis. 2001; 33:883-90.
21. Zervos MJ, Heyder AM, Leroy B. Oral telithromycin 800 mg once daily for 5 days versus cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitis. J Int Med Res. 2003; 31:157-69.
22. Aubier M, Aldons PM, Leak A et al. Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis. Respir Med. 2002; 96:862-71.
23. Buchanan PP, Stephens TA, Leroy B. A comparison of the efficacy of telithromycin versus cefuroxime axetil in the treatment of acute bacterial maxillary sinusitis. Am J Rhinol. 2003; 17:369-77.
24. Ferguson BJ, Guzzetta RV, Spector SL et al. Efficacy and safety of oral telithromycin once daily for 5 days versus moxifloxacin once daily for 10 days in the treatment of acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg. 2004; 131:207-14.
25. Luterman M, Tellier G, Lasko B et al. Efficacy and tolerability of telithromycin for 5 or 10 days vs amoxicillin/clavulanic acid for 10 days in acute maxillary sinusitis. Ear Nose Throat J. 2003; 82:576-90.
26. Shi J, Montay G, Chapel S et al. Pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairment. J Clin Pharmacol. 2004; 44:234-44.
27. Food and Drug Administration. FDA briefing package: Ketek (telithromycin). www.fda.gov/ohrms/dockets/ac/01/briefing/3746b_02_FDA.pdf (accessed 2007 Jan 31).
28. Food and Drug Administration. Antiinfective drugs advisory committee meeting proceedings, April 26, 2001. www.fda.gov/ohrms/dockets/ac/01/ transcripts/3746t1.html (accessed 2007 Jan 31).
29. Mathews AW. Fraud, errors taint a key study of widely used Sanofi drug; despite some faked results, FDA approves antibiotic; one doctor's cocaine use; company defends safety. Wall St J. 2006; May 1:A1,A12.
30. Food and Drug Administration. FDA public health advisory: Ketek (telithromycin) tablets. www.fda.gov/cder/drug/advisory/telithromycin.htm (accessed 2006 Dec 22).
31. Food and Drug Administration. FDA completes safety assessment of Ketek new safety information to be added to product labeling. www.fda.gov/bbs/topics/ NEWS/2006/NEW01401.html (accessed 2006 Dec 22).
32. Ross DB. The FDA and the case of Ketek. N Engl J Med. 2007; 356:1601-4.
33. Soreth J, Cox E, Kweder S et al. Ketek - the FDA perspective. N Engl J Med. 2007; 356:1675-6. Letter.
34. Food and Drug Administration. Detailed view: safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER) - June 2006. www.fda. gov/medwatch/safety/2006/jun06.htm (accessed 2007 Oct 1).
35. Food and Drug Administration. FDA announces label and indication changes for the antibiotic Ketek. www.fda.gov/bbs/topics/NEWS/2007/NEW01561.html (accessed 2007 Feb 27).